Skip to main content
Robert Rifkin, MD, Oncology, Denver, CO

RobertMelvinRifkinMD

Oncology Denver, CO

Hematologic Oncology

Physician

Dr. Rifkin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Rifkin's full profile

Already have an account?

  • Office

    1800 N Williams St
    Ste 200
    Denver, CO 80218
    Phone+1 303-388-4876
    Fax+1 303-830-8633

Education & Training

  • University of Arizona College of Medicine-Tucson
    University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 1986 - 1988
  • HCA HealthONE/Sky Ridge Medical Center
    HCA HealthONE/Sky Ridge Medical CenterResidency, Internal Medicine, 1983 - 1986
  • University of Colorado
    University of ColoradoInternship, Internal Medicine, 1982 - 1983
  • University of Colorado School of Medicine Anschutz Medical Campus
    University of Colorado School of Medicine Anschutz Medical CampusClass of 1982

Certifications & Licensure

  • AZ State Medical License
    AZ State Medical License 1987 - 2027
  • CO State Medical License
    CO State Medical License 1984 - 2025
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Hematology
    American Board of Internal Medicine Hematology
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: ...
    Robert M. Rifkin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect¬ MM Registry
    Robert M. Rifkin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...
    Robert M. Rifkin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazo... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Initial Data from a Phase 2, Non-Comparative Study 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) – Effectiveness in Routine Clinical Practice Is Similar to t... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Understanding Multiple Myeloma Treatment Patterns and Sequencing with Robert Rifkin, MD, FACP
    Understanding Multiple Myeloma Treatment Patterns and Sequencing with Robert Rifkin, MD, FACPFebruary 6th, 2023
  • CU Strategic Plan: Robust Research Goals Ahead
    CU Strategic Plan: Robust Research Goals AheadSeptember 16th, 2021
  • US Oncology Research Announces Schedule of Presentations at the Virtual 2020 American Society of Hematology Annual Meeting and Exposition
    US Oncology Research Announces Schedule of Presentations at the Virtual 2020 American Society of Hematology Annual Meeting and ExpositionDecember 2nd, 2020
  • Join now to see all

Professional Memberships